141 related articles for article (PubMed ID: 28707321)
21. Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility of oral cancer cells.
Parvathy M; Sreeja S; Kumar R; Pillai MR
BMC Cancer; 2016 May; 16 Suppl 1(Suppl 1):293. PubMed ID: 27229476
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling.
Sementino E; Kadariya Y; Cheung M; Menges CW; Tan Y; Kukuyan AM; Shrestha U; Karchugina S; Cai KQ; Peri S; Duncan JS; Chernoff J; Testa JR
Mol Cancer Res; 2022 May; 20(5):699-711. PubMed ID: 35082167
[TBL] [Abstract][Full Text] [Related]
23. MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation.
Colecchia D; Rossi M; Sasdelli F; Sanzone S; Strambi A; Chiariello M
Autophagy; 2015; 11(10):1790-802. PubMed ID: 26291129
[TBL] [Abstract][Full Text] [Related]
24. Systemic analysis of the expression and prognostic significance of PAKs in breast cancer.
Dang Y; Guo Y; Ma X; Chao X; Wang F; Cai L; Yan Z; Xie L; Guo X
Genomics; 2020 May; 112(3):2433-2444. PubMed ID: 31987914
[TBL] [Abstract][Full Text] [Related]
25. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
[TBL] [Abstract][Full Text] [Related]
26. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
27. [Expression of BCR/ABL fusion gene in circulating endothelial cells from chronic myelogenous leukemia patients and its clinical significance].
Wu JY; Huang L; Zhou JF; Pei RZ; Ma JX; Zhang PS; Liu XH; DU XH; Chen D; Sha KY; Li SY; Cao JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):927-31. PubMed ID: 25130805
[TBL] [Abstract][Full Text] [Related]
28. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
29. Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Rana A; Ali GM; Ali S; Khan A; Sabiha B; Malik S; Riaz AM; Farooqi AA
J Cancer Res Ther; 2013; 9(1):3-5. PubMed ID: 23575065
[TBL] [Abstract][Full Text] [Related]
30. P21-activated kinase in inflammatory and cardiovascular disease.
Taglieri DM; Ushio-Fukai M; Monasky MM
Cell Signal; 2014 Sep; 26(9):2060-9. PubMed ID: 24794532
[TBL] [Abstract][Full Text] [Related]
31. Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.
Ohyashiki JH; Umezu T; Ohyashiki K
Curr Opin Hematol; 2016 May; 23(3):268-73. PubMed ID: 26866730
[TBL] [Abstract][Full Text] [Related]
32. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
33. miR-137 inhibits proliferation of melanoma cells by targeting PAK2.
Hao S; Luo C; Abukiwan A; Wang G; He J; Huang L; Weber CE; Lv N; Xiao X; Eichmüller SB; He D
Exp Dermatol; 2015 Dec; 24(12):947-52. PubMed ID: 26186482
[TBL] [Abstract][Full Text] [Related]
34. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
35. Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling.
Koh W; Mahan RD; Davis GE
J Cell Sci; 2008 Apr; 121(Pt 7):989-1001. PubMed ID: 18319301
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
37. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.
Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS
J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101
[TBL] [Abstract][Full Text] [Related]
38. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
[TBL] [Abstract][Full Text] [Related]
39. P21-activated kinase 2 (PAK2) regulates glucose uptake and insulin sensitivity in neuronal cells.
Varshney P; Dey CS
Mol Cell Endocrinol; 2016 Jul; 429():50-61. PubMed ID: 27040307
[TBL] [Abstract][Full Text] [Related]
40. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
